To include your compound in the COVID-19 Resource Center, submit it here.

Novartis' Tasigna gets treatment-free remission FDA label expansion

FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some chronic myelogenous leukemia (CML) patients

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE